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MiceActivation of adenosine receptors modiﬁes the action of classic neurotransmitters (i.e. dopamine, glutamate
and acetylcholine) and other neuromodulators, like vasoactive intestinal peptide (VIP), calcitonin gene-
related peptide (CGRP) and neuropeptide S (NPS). Similarly to adenosine, NPS is involved in the regulation of
stimulus and response to fear and arousal. Thus, the present study investigates the effects of NPS on locomotor
activity in mice treated with or without α,β-methylene adenosine 5′-diphosphate (AOPCP), the inhibitor of
ecto-5′-nucleotidase. Additionally, we evaluate the activity of ecto-5′-nucleotidase in brain slices of mice
treated with or without NPS. Male adult CF-1 mice received i.c.v. NPS as 0.1 nmol injection with or without
pre-treatment with 1 nmolα,β-methylene adenosine 5′-diphosphate (AOPCP), the selective inhibitor of ecto-
5′-nucleotidase, to evaluate locomotor activity. In another set of experiments, mice received i.c.v. infusion of
0.1 nmol NPS to assay enzymatic activity in brain slices. The results demonstrated that the pre-treatment with
AOPCP, which was inactive per se, prevented NPS-induced hyperlocomotion in mice. The dose of 0.1 nmol
NPS was efﬁcient to induce hyperlocomotion in animals during the observation period in the activity cage.
Regarding enzymatic activity, i.c.v. NPS injection did not induce any signiﬁcant alterations in ATP and AMP
hydrolysis in striatum and hippocampus brain slices of mice. The present study shows that the
hyperlocomotor effect of NPS depends on the ecto-5′-nucleotidase activity.iofísica e Farmacologia Centro
eral do Rio Grande do Norte,
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Neuropeptide S (NPS) is a 20-amino acid peptide recently identiﬁed
in the brain and peripheral tissues of distinct species of vertebrates.
This peptide is the endogenous ligand of a G-protein coupled receptor
named NPSR receptor (Xu et al., 2004). In cells expressing the
recombinant NPS receptor, NPS increases Ca2+ mobilization, intracel-
lular cAMP formation and phosphorylation of extracellular signal
regulated-kinase (ERK1/2) (Xu et al., 2004; Reinscheid et al., 2005).
NPS receptor (NPSR) is expressed in the medial amygdala, substantianigra pars compacta, subiculum, dorsal raphe, hypothalamus, thalamus,
in the pyramidal cell layer of the ventral hippocampus, and was widely
distributed in the cortex (Leonard and Ring, 2011). Higher NPS levels
were found in cortex, hypothalamus, amygdala, endopiriform nucleus,
subiculum, and nuclei of the thalamic midline, while moderate levels
were found in substantia nigra (Xu et al., 2007). Conversely, NPS
precursor mRNA is found highly expressed only in a cluster of neurons
located between the locus coeruleus and Barrington's nucleus (Xu et al.,
2004).
The neuroanatomical expression of NPS and its receptor NPSR
supports the role played by this peptidergic system in physiological
functions such as anxiety (Xu et al., 2004; Jungling et al., 2008;
Leonard et al., 2008; Rizzi et al., 2008; Vitale et al., 2008), arousal (Xu
et al., 2004; Rizzi et al., 2008), food intake (Beck et al., 2005; Smith
et al., 2006), locomotion (Xu et al., 2004; Roth et al., 2006; Smith et al.,
2006; Leonard et al., 2008; Okamura et al., 2008; Rizzi et al., 2008;
Castro et al., 2009b), nociception (Li et al., 2009), memory (Han et al.,
2009; Jungling et al., 2008) and drug addiction (Cannella et al., 2009,
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world have revealed that NPS promotes hyperlocomotion in mice (Xu
et al., 2004; Roth et al., 2006; Leonard et al., 2008; Rizzi et al., 2008;
Castro et al., 2009a, 2009b; Boeck et al., 2010), and rats (Smith et al.,
2006).
Recently, a study demonstrated that the effects evoked by NPS on
mouse locomotion are similar to those observed after the adminis-
tration of stimulating caffeine doses (Rizzi et al., 2008). Also, NPS and
caffeine act in the regulation of wakefulness states (Xu et al., 2004;
Rizzi et al., 2008), and food intake (Beck et al., 2005). Probably, there is
an interaction between the adenosinergic and NPS–NPSR receptor
systems, because Lage et al. (2006), using the PCR technique, have
shown alterations in expression of mRNA NPS and NPSR receptor in
rat hypothalamus and brainstem after acute and repeated caffeine
treatments. Very recently, our research group has demonstrated the
inhibitory effect induced by caffeine and ZM 241385, a selective
adenosine A2A receptor antagonist, on hyperlocomotion induced by
NPS in mice (Boeck et al., 2010).
Adenosine, operating via inhibitory adenosine A1 receptors or
excitatory adenosine A2A receptors, has widespread modulatory
actions in the nervous system and may interfere with the action of
other classic neurotransmitters and neuromodulators (Ribeiro, 1999).
Interestingly enough, in a synaptic cleft, adenosine available could
have two distinct sources: (1) it may come from the release via bi-
directional nucleoside transporter; (2) and/or from adenine nucleo-
tides released, which are degraded by a chain of ecto-nucleotidases
(Hoehn and White, 1990; Craig and White, 1993; Cunha et al., 1996).
The most relevant ecto-enzymes involved in this chain are those
of the ecto-nucleoside triphosphate diphosphohydrolases family (E-
NTPDases), which hydrolyze nucleoside tri- and di-phosphates. At
least eight different members of the NTPDase family have been
discovered, cloned and studied over the last few years. NTPDases1, 2,
and 3 are expressed in nervous tissue and mediate the termination of
ATP signaling in the synaptic cleft (Zimmermann et al., 1998; Wink
et al., 2006). The produced nucleoside monophosphates in the cleft
are hydrolyzed by ecto-5′-nucleotidase (E.C. 3.1.3.5) (Fredholm et al.,
2005; Robson et al., 2006), that is a pivotal step in extracellular
adenosine production from the enzymatic chain (James andRichardson,
1993). It has been suggested that adenosine release leads to preferential
A1 receptor activation, while adenosine formed from the ecto-
nucleotidase pathway leads to favored adenosine A2A receptor acti-
vation (Cunha et al., 1996; Boeck et al., 2005). In this context, our
group recently demonstrated the inhibitory effect inducedby caffeineor
ZM 241385, a selective A2A receptor antagonist, on hyperlocomotion
induced by NPS in mice (Boeck et al., 2010).
Thus, considering that adenosine plays a modulatory effect in the
hyperlocomotion evoked by NPS, the present study aimed at
investigating whether the involvement of adenosine in the hyperlo-
comotor effect of NPS is due to its production via ecto-nucleotidases
pathway. To test this hypothesis we pre-treated mice with α,β-
methylene-adenosine 5′-diphosphate (AOPCP), the speciﬁc ecto-5′-
nucleotidase inhibitor, before NPS challenge. The present study also
investigated whether NPS treatment is able to modify the E-NTPDase
and ecto-5′-nucleotidase activities in hippocampal and striatal mouse
brain slices.
2. Materials and methods
2.1. Materials
Adenosine 5′-triphosphate (ATP), adenosine 5′-monophosphate
(AMP) and α,β-methylene adenosine 5′-diphosphate (AOPCP) were
obtained from Sigma (St Louis, MO, USA). Human NPS was
synthesized by Dr R. Guerrini, Department of Pharmaceutical Science
and Biotechnology Center, University of Ferrara, according to
published methods (Roth et al., 2006). NPS was dissolved in salinesolution (NaCl 0.9 g%, w/v) and intracerebroventricularly (i.c.v.)
administered in mice. AOPCP had its pH adjusted with NaOH 0.1 M
and was diluted in saline solution. All other chemicals were of
analytical reagent grade and purchased from local suppliers.
2.2. Animals and surgical procedure
Male albino CF-1 mice (2–3 months of age, 30–35 g) were ob-
tained from our breeding colony (UNESC). Six animals were housed
per cage with food and water freely available and were maintained on
a 12-h light/dark cycle (lights on at 7:00 a.m.). All experimental
procedures involving animals were performed in accordance with the
National Institute of Heath's Guide for the Care and Use of Laboratory
Animals and the recommendations of the Sociedade Brasileira de
Ciências em Animais de Laboratório (SBCAL) for animal care, designed
to minimize suffering and limit the number of animals used. To avoid
circadian variations all experimentswere carried out between 8:00 a.m.
and 1:00 p.m. This study was approved by the local ethics committee
(Comitê de Ética no Uso de Animais da Universidade do Extremo Sul
Catarinense, no. 045/2009).
Surgery and i.c.v. infusion techniqueswere conducted according to
Schmidt et al. (2000). Naïve mice were anesthetized with 7% chloral
hydrate (w/v, 10 mL/kg body weight, i.p.). In a stereotaxic apparatus,
the mouse skull skin was removed and an i.c.v. guide cannula (27-
gauge) was unilaterally implanted 1.0 mm posterior to bregma,
1.0 mm to the right of the midline and 1.0 mm above the right lateral
brain ventricle. The guide cannula was implanted 1.5 mm ventral to
the superior surface of the skull and ﬁxed with jeweler's acrylic
cement. In the experiments, performed 48 h after surgery, an i.c.v.
infusion was performed using a 30-gauge cannula that was ﬁtted into
the implanted guide cannula and connected by a polyethylene tube to
a Hamilton microsyringe. The tip of the infusion cannula protruded
1 mm beyond the guide cannula, aiming at the lateral brain ventricle.
After experiments, methylene blue (4 μL) was injected through the
cannula and animals without dye in the lateral brain ventricle were
discarded.
2.3. Treatments
Mice received i.c.v. vehicle injection (saline solution; 5 μL) or
AOPCP (1 nmol; 5 μL) just before testing locomotor activity. Five
minutes following AOPCP administration, mice received i.c.v. vehicle
or NPS injection (0.1 nmol; 1 μL) and their locomotor activity was
evaluated for 25 min. Previous studies performed in our laboratory
showed that this dose of NPS produces a higher stimulatory effect on
locomotion (Castro et al., 2009a; Castro et al., 2009b; Boeck et al.,
2010). The dose of AOPCP employed in the present study was chosen
based on the previous study in mice (Saute et al., 2006).
In another set of experiments, mice received vehicle or NPS
(0.1 nmol) in the lateral ventricle as a constant volume of 1 μL, 5 min
before the enzymatic assay.
2.4. Locomotor activity assay
An infrared beam array cage (Insight Equipments, Ribeirão Preto,
Brazil) connected to a PC was used to assess locomotor activity in
mice. The infrared beam array cage consists of a cubicle made of clear
Perspex (48×50 cm) surrounded by 50-cm-high walls. Two blocks
facing each other and containing an infrared array recorded horizontal
activity, and a similar system assessed vertical activity. Just after i.c.v.
vehicle or AOPCP injection non-habituated animals were gently
placed on the center of the arena and were individually allowed to
explore the apparatus for 5 min. Mice were gently removed from the
cage, received an i.c.v. vehicle or NPS injection and were returned to
the apparatus to explore it for another 25-min period (totaling 30 min
of observation). All behavioral experiments were conducted in a well
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behavioral evaluation of each mouse, the arena was cleaned with 10%
ethanol solution. Each mouse was individually evaluated once for
locomotor activity, for a 30-min period. The total distance covered
by each animal was assessed based on 5-min time intervals.
2.5. Nucleotides hydrolyses assay
Five minutes after i.c.v. vehicle or NPS injection mice were killed
by decapitation and the brains were rapidly removed and transferred
to a pre-warmed HEPES-buffered salt solution with the following
composition: 120 mM NaCl, 5 mM KCl, 2 mM CaCl2 and 10 mM
glucose (pH 7.4) and gassed with a 95% O2/5% CO2 mixture
(incubation medium). The brains were cut longitudinally, their
hippocampi and striatum dissected and sliced transversely as
400-μm-thick slices on a Mcllwain tissue chopper. Two slices per
tube (approx. 0.15 mg protein) were preincubated for 10 min at 37 °C
with 400 μL of the incubation medium (described above). To measure
ATP and AMP hydrolyses the slices were incubated with ATP or AMP
(1 mM, ﬁnal concentration) for 20 min at 37 °C. Following incubation,
an aliquot of the assay medium was removed and mixed with
trichloroacetic (TCA) to a ﬁnal concentration of 5%. A sample of the
supernatant was taken for the assay of inorganic phosphate (Pi)
release by colorimetric determination (Chan et al., 1986). Non-
enzymatic Pi released from nucleotide in the assay medium without
cells and Pi released from cells incubated without nucleotide were
subtracted from the total Pi released during nucleotide hydrolysis, to
produce enzymatic activity values (nmol Pi/mg protein per min). All
experimental conditions adopted were previously investigated in
order to ensure the linearity of enzymatic reaction and the
preservation of cellular viability until the end of the experiment (data
not shown). Protein was determined using bovine serum albumin as
standard (Bradford, 1976).
2.6. Statistical analysis
Behavioral data were presented as mean values±S.E.M. (standard
error of the mean) and each value reﬂected the mean of 10–14
animals per group. The effects of the combined administration of NPS
and AOPCP were statistically analyzed using a two-way ANOVA with
NPS and AOPCP as main factors, followed by the Tukey's post hoc test.
Enzymatic data are presented as mean values±S.E.M. (standard errorFig. 1. Effect of the i.c.v. NPS injection (0.1 nmol; 1 μL) with or without AOPCP (1 nmol; 5 μ
cages for 30 min. Five minutes after the administration of saline or AOPCP, mice were trea
evaluate cumulative activity of mice. Data are shown as mean±S.E.M. (10–14 mice/group)
followed by the Tukey's test.of the mean) and each value reﬂected the mean of triplicate samples
from 8 to 10 animals per group. The effect of the NPS was statistically
analyzed using the Student's t-test. Differences were considered
signiﬁcant when Pb0.05. Results were analyzed by STATISTICA®
software version 7.0 (StatSoft, Inc., USA).
3. Results
Fig. 1 shows the effect of pre-treatment of ecto-5′-nucleotidase
inhibitor AOPCP on NPS-induced hyperlocomotion. Non-habituated
mice treated with AOPCP did not show any changes in locomotor
activity, when compared to saline treated mice during the ﬁrst 5-min
period on the arena or even throughout the experimental period
(Fig. 1A). Mice treated with NPS displayed increased locomotor
activity, with signiﬁcant effect beginning 10 min following the NPS
injection (F(1.41)=7.277; P=0.01) (Fig. 1A). However, mice pre-
treated with AOPCP before NPS administration did not display the
NPS-induced hyperlocomotion, an effect statistically dependent on
the interaction of AOPCP and NPS for all periods (20 min–F(1.41)=
5.771; P=0.02; 30 min–F(1.41)=7.839; P=0.008). When the
activity of mice was evaluated as cumulative distance traveled during
30 min, AOPCP effectively induced the prevention on NPS-induced
hyperlocomotion (F(1.41)=7.189; P=0.015) reaching basal values
(Fig. 1B).
The measurement of ecto-NTPDase activities was evaluated in
slices of brain areas following NPS injection in mice (Fig. 2). ATP
or AMP hydrolysis in striatum (tATP=−0.806; P=0.432; tAMP=
−0.364; P=0.720) (Fig. 2A) or hippocampus (tATP=−1.998;
P=0.062; tAMP=−0.999; P=0.334) (Fig. 2B) was not altered by NPS
(PN0.05 for all nucleotides at each brain area).
4. Discussion
In the present study, we investigated the origin of adenosine
that contributes to NPS-induced hyperlocomotion in mice using
the combination of NPS and a selective inhibitor of the ecto-5′-
nucleotidase, responsible for the inhibition of extracellular adenosine
production from nucleotides released. The present data conﬁrmed
that 0.1 nmol NPS i.c.v injection substantially increased mouse
spontaneous locomotion, according to other studies (Xu et al., 2004;
Roth et al., 2006; Leonard et al., 2008; Rizzi et al., 2008; Castro et al.,
2009a; Castro et al., 2009b). The present data are also in line with ourL) on the spontaneous locomotor activity assessed in mice kept in infrared beam array
ted with saline or NPS and (A) the locomotor activity was recorded for 25 min (B) to
. *Pb0.05 vs. control group and #Pb0.05 vs. NPS group, according to two-way ANOVA
Fig. 2. Effect of the i.c.v NPS injection (0.1 nmol; 1 μL) on the ecto-nucleotidase
activities in slices from hippocampus or striatum of mice. Enzymatic data are presented
as mean values±S.E.M. and each value reﬂects the mean of triplicate samples from
8 to 10 animals per group. The effect of NPS was statistically analyzed using the
Student's t-test.
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effects of NPS in rodents that can nevertheless be blunted by
adenosine A2A receptor antagonists (Boeck et al., 2010).
Ecto-nucleotidases break down the adenine nucleotides in
stages to produce free extracellular adenosine at the terminal
step (Zimmermann, 1999). For example, the extrasynaptic enzyme
ecto-nucleoside triphosphate diphosphohydrolase 1 (EC 3.6.1.5; E-
NTPDase1, previously identiﬁed as ecto-ATPDase, ecto-apyrase or
CD39) converts ATP and ADP to AMP in cultured hippocampal neurons
(Boeck et al., 2002). The ﬁnal and critical step of conversion of AMP to
adenosine is carried out by ecto-5′-nucleotidase (Dunwiddie et al.,
1997). Thus, to fully deﬁne the roles that individual species play in
purinergic signaling, it is useful to prevent the extracellular metabolism
of purines such as AMP (Cunha et al., 2000; Mihaylova-Todorova et al.,
2002). In the present study, AOCPC was employed in order to inhibit
ecto-5′-nucleotidases activity at dose previously shown to inhibit the
behavioral responses to guanine-based nucleotides on pain and
memory in mice (Saute et al., 2006; Schmidt et al., 2008). Also, AOPCP
induces decrease on extracellular adenosine levels after injection of
NMDA in the striatumof rat (Delaney et al., 1998) and it blocks release of
purines in response to hypothalamic defense area stimulation, which it
was observed that adenosine is predominantly released in the nucleus
tractus solitarii (Dale et al., 2002). Previous in vitro studies using AOPCP
demonstrated that the nucleotides released are the source of adenosine
in cortical slices and synaptosomes after glutamate incubation (Hoehn
and White, 1990; Craig and White, 1993). Thus, the studies demon-
strated that thenucleosides (adenosine or guanosine)were produced in
the extracellular space by the prior release of nucleotide (i.e. ATP).
In the present study, we also investigated the participation of
adenosine produced by ecto-5′-nucleotidase during the stimulatory
effects of NPS in brain of mice. Our ﬁndings are the ﬁrst evidence that
the administration of AOPCP does not signiﬁcantly alter per se mouse
locomotor activity. However, the combined injection of AOPCP and
NPS blocks the effect of NPS as regards the increase in the distance
covered during locomotion, as induced by the neuropeptide (Fig. 1).
Regarding adenosine receptors activation, the ecto-5′-nucleotidase
activity is critical. It has been proposed that one of the possible
mechanisms for extracellular adenosine to preferentially activate
either inhibitory or facilitatory receptors depends on the manner in
which extracellular adenosine was generated. If adenosine is released,
as such, through bidirectional non-concentrative adenosine trans-
porters, it could favor adenosine A1 receptor-mediated inhibition. On
the other hand, if adenosine is formed from the extracellular catabolism
of ATP, it could favor adenosine A2A receptor-mediated facilitation
(Cunha et al., 1996). The preferences of adenosine for its receptors may
be due to the proximal brain distribution of ecto-5′-nucleotidadase andadenosine A2A receptors. In a recent paper we have demonstrated that
the stimulatory effects of NPS on locomotion depend on the activation
of adenosine A2A receptor, while the activation of A1 receptors plays a
minor role in the modulation of NPS effects (Boeck et al., 2010). Taken
together, these results suggested that the adenosine involved in the
hyperlocomotor effects of NPS could be produced by extracellular
catabolism of nucleotides.
In the present study we also investigated whether NPS treatment
could affect the activity of ecto-nucleotidases in the striatum and
hippocampus. Even though we did not observe a signiﬁcant
modiﬁcation in ecto-nucleotidase activities following NPS adminis-
tration (Fig. 2), the participation of this cascade pathway in the
adenosine effect upon NPS cannot be excluded. One of the limitations
in the protocol used in the present study was that the assessment of
enzyme activities in brain slices was performed at the onset of the NPS
effects (i.e. animals were euthanized 5 min after NPS injection). Thus,
in this context, we cannot completely exclude the effects of NPS
(directly or indirectly) on ecto-nucleotidases activity. However, it is
interesting to note that the AOPCP effect is clear; thus, our results
demonstrate that adenosine conversion is also necessary for the in
vivo model of hyperlocomotion induced by NPS.
A recent study revealed that NPS suppressed the increase in
extracellular acetylcholine levels induced byMK-801 (NMDA receptor
antagonist) in the retrosplenial cortex (Okamura et al., 2010). Also,
adenosine modulates extracellular acetylcholine levels, because
adenosine A2A receptors have been shown to facilitate the release of
most neurotransmitter types, including acetylcholine, in different
extra-striatal brain regions (Jin and Fredholm, 1997). Thus, the NPS
modulation probably depends on the activation of adenosine A2A
receptors. Other studies have explored this idea, showing that the
peptidergic modulation of excitatory synaptic transmission in the
hippocampus by G-protein coupled receptors, operated by calcitonin
gene-related peptide (CGRP) and vasoactive intestinal peptide (VIP),
is strictly dependent on the activation of A2A receptors (Cunha-Reis et
al., 2008; Sebastião et al., 2000). Conversely, Ruzza et al. (2010)
recently showed that the NPSR receptor antagonist SHA68 did not
affect the hyperlocomotor effect of caffeine in mice. These ﬁndings
suggest that the excitatory effects of caffeine are not dependent on
NPSR receptors.
Thus, the possible role of adenosine depends on physiological
needs, i.e. to contribute for the facilitation of synaptic transmission,
possibly through an A2A receptor-induced A1 receptor desensitiza-
tion (Lopes et al., 1999), which in turn would contribute to the
effect of NPS on locomotor activity. We hypothesized that the
modulatory effect of adenosine receptors under NPS-induced
stimulation could be due to a common protein-G signaling pathway
shared by both systems, since both adenosine A2A and NPSR
receptors are positively coupled to adenylate cyclase. However,
the interaction of adenosine and NPS in the stress, anxiety, arousal
and sleep, and food intake as being likewise modulated by NPS
should be further investigated.
In conclusion, the present results demonstrate that the NPS-
induced hyperlocomotion in mice is dependent on ecto-5′-nucleotid-
ase activity; however, it should be mentioned that this assay was
performed 5 min after NPS injection, thus longer periods after NPS-
injection are required to assess possible effects. Finally, these data
corroborate the view that an adenosinergic tonus is essential for the
hyperlocomotor effect evoked by NPS.
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